<DOC>
	<DOCNO>NCT02579759</DOCNO>
	<brief_summary>The purpose study determine whether PXT3003 effective safe treatment Charcot-Marie-Tooth disease - Type 1 A ( CMT1A ) . This double-blind study ass parallel group 2 dos PXT3003 compare Placebo CMT1A patient treat 15 month .</brief_summary>
	<brief_title>Phase III Trial Assessing Efficacy Safety PXT3003 CMT1A Patients ( PLEO-CMT )</brief_title>
	<detailed_description>PXT3003 , fix dose combination ( RS ) -baclofen , naltrexone hydrochloride D-sorbitol select via Systems Biology approach develop Pharnext , aim low toxic PMP22 gene over-expression CMT1A .</detailed_description>
	<mesh_term>Tooth Diseases</mesh_term>
	<mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
	<mesh_term>Nerve Compression Syndromes</mesh_term>
	<mesh_term>Hereditary Sensory Motor Neuropathy</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Male female , age 16 65 year ; Patient proven genetic diagnosis CMT1A ; Mildtomoderate severity assess CharcotMarieTooth Neuropathy Score ( version 2 ) score &gt; 2 ≤18 ; Muscle weakness least foot dorsiflexion ; Motor nerve conduction ulnar nerve least 15 m/sec ; Providing sign write informed consent participate study willing able comply study procedure schedule visit . Any associated cause peripheral neuropathy diabetes ; Patient another significant neurological disease concomitant major systemic disease ; Clinically significant history unstable medical illness since last 30 day ( unstable angina , cancer… ) may jeopardize participation study ; Significant hematologic disease , hepatitis liver failure , renal failure ; Limb surgery within six month randomization plan trial completion ; Clinically significant abnormality prestudy laboratory evaluation , physical evaluation , electrocardiogram ( ECG ) ; Elevated ASAT/ALAT ( &gt; 3 x ULN ) elevate serum creatinine level ( &gt; 1.25 x ULN ) ; History recent alcohol drug abuse nonadherence treatment experimental protocol ; Patient use unauthorized concomitant treatment include limited baclofen , naltrexone , sorbitol ( pharmaceutical form ) , opioids , levothyroxin potentially neurotoxic drug amiodarone , chloroquine , cancer drug susceptible induce peripheral neuropathy . Patient can/agrees stop medication 4 week randomization whole study duration include ; Female childbearing potential ( apart patient use adequate contraceptive measure ) , pregnant breast feeding ; Known hypersensitivity individual component PXT3003 ; Porphyria contra indication baclofen , may also induce neuropathy ; Suspected inability complete study followup ( foreign worker , transient visitor , tourist others followup evaluation assure ) ; Limited mental capacity psychiatric disease render subject unable provide write informed consent comply evaluation procedure ; Patient participate another trial investigational drug ( ) within past 30 day ; If patient family , live household , already include study , possible include another patient family avoid mix therapeutic unit ; therefore would risk inversion blind treatment could jeopardize interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PXT3003</keyword>
</DOC>